Pharma giant Cipla has received the approval from the Food and Drug Administration for its abbreviated new drug application (ANDA) for anti-HIV/AIDS drug Slamivudine,
Pharma giant Cipla has received the approval from the Food and Drug Administration for its "abbreviated new drug application (ANDA) for anti-HIV/AIDS drug Slamivudine," according to a posting on the FDA site.
The website reported that the tentative approval for ANDA is for an oral solution with strength of 10mg per ml. The new drug belongs to a class of drugs called as nucleoside reverse transcriptase inhibitors. It stops the replication of the HIV virus and hepatitis B virus as well.
